Proactive - Interviews for investors Podcast Por Proactive arte de portada

Proactive - Interviews for investors

Proactive - Interviews for investors

De: Proactive
Escúchala gratis

Obtén 3 meses por US$0.99 al mes
Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business. Economía Finanzas Personales Política y Gobierno
Episodios
  • ReconAfrica confirms hydrocarbon pay at Kavango West 1X well in Namibia

    ReconAfrica confirms hydrocarbon pay at Kavango West 1X well in Namibia
    Dec 3 2025
    Reconnaissance Energy Africa or ReconAfrica CEO Brian Reinsborough joined Steve Darling from Proactive to announce the results from the company’s Kavango West 1X exploration well, located on Petroleum Exploration Licence 73 in onshore Namibia. The well delivered encouraging results, encountering approximately 400 metres of gross hydrocarbon-bearing section within the Otavi carbonate interval, as identified by wireline logging data. Reinsborough told Proactive that detailed evaluation of the logs confirms 64 net metres of hydrocarbon pay, supported by both wireline interpretation and strong mud log anomalies. In addition, the company identified a further 61 metres (approximately 200 feet) of hydrocarbon shows in deeper intervals. These zones are interpreted to contain naturally fractured limestone reservoirs, a geological feature that could significantly enhance the flow potential and overall deliverability of hydrocarbons. Following these positive results, ReconAfrica’s forward program will now focus on comprehensive well testing to establish commercial flow rates from the most prospective intervals. The company will proceed with testing due to the strong indications of hydrocarbon-saturated reservoirs across multiple zones, based on the combined evidence from wireline logs, oil and gas shows, and interpreted natural fracture systems within the limestone units. A production test is planned to evaluate the deliverability characteristics of the key intervals within the Otavi carbonate section. The test will be conducted using 5-inch production casing and Tubing-Conveyed Perforations (TCP), allowing the company to selectively perforate specific pay zones. These selections will be based on intervals where hydrocarbon pay has been confirmed on wireline logs and where the most significant oil and gas shows were observed. Reinsborough noted that the upcoming testing phase represents an important next step in determining the commercial potential of the Kavango West 1X well and further advancing ReconAfrica’s exploration efforts across the broader Kavango Basin in Namibia. #proactiveinvestors #reconnaissanceenergyafricaltd #tsxv #reco #otcqx #recaf #NamibiaOil #ProspectI #OilExploration #EnergyUpdate #OnshoreDrilling #OilAndGasNews #AfricanEnergy #OilDiscovery #EnergyInvesting #OilExploration #NamibiaOil #EnergyInvesting #KavangoBasin #BrianReinsborough #OilAndGas #InvestorUpdate #ProactiveInvestors #AngolaEnergy
    Más Menos
    4 m
  • Tonix wins FDA clearance to launch phase 2 trial for major depressive disorder

    Tonix wins FDA clearance to launch phase 2 trial for major depressive disorder
    Dec 3 2025
    Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug (IND) application for TNX-102 SL, enabling Tonix to begin clinical development of the drug for major depressive disorder (MDD) in adults. Dr. Lederman explained that the IND clearance allows Tonix to initiate the potentially pivotal Phase 2 HORIZON study — a 6-week, randomized, double-blind, placebo-controlled trial evaluating TNX-102 SL as a first-line monotherapy. The study will enroll approximately 360 adults across about 30 U.S. clinical sites. Participants must be 18 years or older and currently experiencing a moderate to severe major depressive episode. The trial will compare TNX-102 SL 5.6 mg, taken sublingually at bedtime, against placebo. The primary endpoint is change from baseline at Week 6 on the MADRS or Montgomery–Åsberg Depression Rating Scale total score. Secondary measures include global impression scores, anxiety assessments, and indicators of sleep disturbance. Tonix expects to begin enrolling patients in mid-2026. Dr. Lederman emphasized the significant need for new treatment options in MDD — a serious and widespread psychiatric condition affecting more than 21 million adults in the United States each year. Symptoms commonly include persistent sadness or loss of interest, sleep and appetite disruption, fatigue, impaired concentration, and feelings of worthlessness. These symptoms must be present for at least two weeks and cause meaningful impairment to daily life. Tonix aims to advance TNX-102 SL as a novel therapeutic option to address this substantial unmet medical need. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #DepressionTreatment #TNX102SL #MajorDepressiveDisorder #MentalHealthInnovation #SleepTherapy #FDAApproval #BiotechNews
    Más Menos
    3 m
  • Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial

    Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial
    Dec 3 2025
    Lantern Pharma CEO Panna Sharma joined Steve Darling from Proactive to discuss the company’s latest clinical milestone and its broader mission to transform oncology drug development through the use of artificial intelligence, machine learning, and genomic data. Lantern’s proprietary RADR® AI platform integrates billions of biological and clinical data points to identify predictive biomarkers, forecast drug response, and design more targeted and efficient clinical trials aimed at delivering precision cancer therapies to patients. The company announced additional details from its recently completed Phase 1a dose-escalation study of LP-184, its lead drug candidate. The trial produced encouraging results, demonstrating durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which exhibited deficiencies in DNA damage repair pathways—an area where LP-184 is designed to be particularly effective. Sharma told Proactive that the Phase 1a study successfully met all primary endpoints for safety and tolerability, while also clearly establishing a recommended Phase 2 dose (RP2D). He emphasized that these outcomes validate both the scientific rationale behind LP-184 and the predictive capabilities of Lantern’s AI-driven development approach. Building on these positive results, Lantern Pharma is now advancing an ambitious precision oncology strategy that includes multiple biomarker-guided Phase 1b/2 clinical trials. These studies will target major cancer indications such as triple-negative breast cancer (TNBC), glioblastoma multiforme (GBM), non-small cell lung cancer, and advanced bladder cancer. The commercial potential for LP-184 is significant. Lantern and independent industry analysts estimate that the aggregate annual market opportunity for the drug across these and additional targeted indications could exceed $10 billion. Preclinical models have shown nanomolar potency, while early clinical data indicate encouraging durability of response even in heavily pre-treated patient populations. LP-184 has also received important regulatory recognition from the U.S. Food and Drug Administration, including Fast Track Designation for TNBC and GBM, as well as Orphan Drug Designation for malignant gliomas, pancreatic cancer, and atypical teratoid/rhabdoid tumors (ATRT). Sharma noted that these designations support an accelerated development pathway as Lantern continues to move LP-184 toward later-stage clinical trials. #proactiveinvestors #laternpharma #nasdaq #ltrn #LanternPharma #PannaSharma #PrecisionOncology #CancerResearch #AIinHealthcare #MachineLearning #Genomics #ClinicalTrials #BiotechNews #OncologyInnovation #LP184 #Phase1a #Phase2Trials #BiomarkerDriven #TripleNegativeBreastCancer #Glioblastoma #LungCancer #BladderCancer #OrphanDrug #FastTrackDesignation #FDA #PrecisionMedicine
    Más Menos
    7 m
Todavía no hay opiniones